Acute myeloid leukemia (AML) cells exhibit a high level of spontaneous apoptosis when cultured in vitro but have a prolonged survival time in vivo, indicating that tissue microenvironment plays a critical role in promoting AML cell survival. In vitro studies have shown that bone marrow-mesenchymal stromal cells (BM-MSC) protect AML blasts from spontaneous and chemotherapy-induced apoptosis. Here we report a novel interaction between AML blasts and BM-MSC which benefits AML proliferation and survival. We initially examined the cytokine profile in cultured human AML compared to AML cultured with BM-MSC and found that macrophage-migration inhibitory factor (MIF) was highly expressed by primary AML, and that interleukin-8 (IL-8) was increased in AML/BM-MSC co-cultures. Furthermore, they provide biologic rationale for therapeutic strategies in AML targeting the microenvironment, specifically MIF and IL-8.
Introduction
Survival of patients with acute myeloid leukemia (AML) is presently poor; two-thirds of young adults and 90% of older adults die of their disease (1) . Even in patients who achieve remission with chemotherapy relapse is common and occurs from minimal residual disease sequestered in protective niches in the bone marrow microenvironment (2) . Accordingly it is envisaged that improved outcomes will come from novel treatment strategies derived from an improved understanding of the biology of AML within the bone marrow microenvironment. AML cells exhibit a high level of spontaneous apoptosis when cultured in vitro but have a prolonged survival time in vivo, indicating that the tissue microenvironment plays a critical role in promoting AML cell survival (3) (4) (5) (6) . Knowledge of the complexity of the bone marrow microenvironment is increasing especially with respect to the bone marrow mesenchymal stromal cells [BM-MSC] which are considered a major protective cell type (7) . BM-MSC generate various factors whose primary functions are to influence tumor cell survival and homing (4, 8, 9) . The apoptotic defect in AML is not cell-autonomous but highly dependent on extrinsic signals derived from their microenvironment. The complex cell-cell interactions between the AML tumor cells and their microenvironment are therefore essential for tumor growth and survival and thus present an attractive target for novel drug therapies.
Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine which under normal conditions regulates cell-mediated immunity and inflammation (10) . In cancer, MIF is overexpressed in a number of solid tumors including breast, prostate and colon cancers (11) (12) (13) . MIF has also been shown to be overexpressed in various blood cancers including chronic lymphocytic leukemia (CLL) (14) . In CLL, MIF is expressed by the malignant cells and induces protective IL-8 release in an autocrine-dependent manner. Blocking either MIF or IL-8 reduces survival of CLL. The increased secretion of IL-8 from tumor cells is thought to have wider significance to the tumor microenvironment. Serum IL-8 is known to be higher in patients with AML, myelodysplasia (MDS) and non-Hodgkin Lymphoma than in normal 4 controls and levels of IL-8 in these patients are similar to those found in patients with multiple organ failure of non-septic origin (15, 16) . Furthermore leukemic blasts from the majority of patients with AML constitutively express IL-8 (17) . In addition, inhibition of the IL-8 receptor, CXCR2 selectively inhibits proliferation of MDS/AML cell lines and patient samples (18) . Together these studies suggest that MIF and IL-8 are functionally important in regulating the survival and proliferation of multiple tumors including AML.
In the present study, we investigate how AML cells program BM-MSC via MIF to produce the survival cytokine IL-8 and characterize the signaling pathways underlying this interdependent cell-cell communication.
Materials and Methods

Materials
Anti-PKC, MAPK and AKT antibodies were purchased from Cell Signaling Technologies.
Anti-CD74, anti-CXCR2, and anti-CXCR4 antibody were purchased from Miltenyi Biotec. All inhibitors were purchased from Tocris. The CD74 blocking antibody was purchased from BD Biosciences. Proteome Profiler Human XL array and recombinant human MIF were purchased from R&D Systems. MIF ELISA was purchased from BioLegend. IL-8 ELISA was purchased from eBiosciences. All other reagents were obtained from Sigma-Aldrich
Cell culture
For primary cell isolation, heparinized blood was collected from volunteers and human peripheral blood mononuclear cells (PBMCs) were isolated by Histopaque (Sigma-Aldrich) density gradient centrifugation. AML samples that comprised less than 80% blasts were purified using the CD34 positive selection kit. Cell type was confirmed by microscopy and flow cytometry. BM-MSC were isolated by bone marrow aspirates from AML patients. 
Results
BM-MSC support AML survival.
The microenvironment supports AML survival and proliferation (4, 5, 19) . Figure 1D ). To verify these observations we carried out IL-8 and MIF specific ELISAs. IL-8 concentrations peak at 8 and 24 hours in the AML/ BM-MSC co-culture supernatants ( Figure 1E ), whereas MIF concentrations were high and at similar levels in AML culture supernatants and AML/ BM-MSC co-culture supernatants ( Figure 1F ).
AML derived MIF induces IL-8 expression in BM-MSC.
Next we looked to determine whether BM-MSC needed direct contact with AML to increase IL-8 expression. RT-PCR showed that IL-8 mRNA from BM-MSC incubated with AML increased by 57 fold when in direct contact (DC) and by 50 fold when in indirect contact (IC) with AML blasts (Figure 2A ). This confirms that direct tumor cell to stromal cell contact is not necessary for AML to induce increased IL-8 expression by BM-MSC. 
MIF induced IL-8 upregulation is mediated through CD74.
Depending on the cellular context and the disease involved, MIF signaling is mediated by its receptors CXCR2 (Interleukin 8 receptor, ILR8) and/or CXCR4 (Stromal-derived factor 1 receptor), and/or CD74 (22, 23) . BM-MSC have been reported to express all three receptors (24) (25) (26) . Using CD105 as a BM-MSC marker to confirm mesenchymal cell phenotype, we
show that CD74 and CXCR4 are expressed but CXCR2 is not expressed on all primary BM-MSC isolated from AML patients ( Figure 3A ). BM-MSC were further characterized using CD73 and CD90, and lack of CD45 expression.
We used specific inhibitors of CXCR2, CXCR4 and CD74 to determine which receptor/s were responsible for MIF induced IL-8 up-regulation. Inhibition of CXCR2 and CXCR4 using pertussis toxin (a GPCR inhibitor) had no effect on MIF induced IL-8 mRNA expression ( Figure 3B) . However, the anti-CD74 blocking antibody inhibited MIF induced IL-8 expression in BM-MSC ( Figure 3C ). These results suggest that CD74 is the dominant receptor in regulating MIF induced IL-8 expression in AML patient derived BM-MSC. To further characterize this interaction we used lentiviral viral mediated knockdown (KD) of CD74 in AML patient derived BM-MSC, confirming reduced mRNA and protein expression of CD74 after transduction with control KD or CD74 KD lentivirus ( Figure 3D ). Furthermore we demonstrate that CD74 knockdown inhibits MIF induced IL-8 mRNA expression in AML patient derived BM-MSC ( Figure 3E ).
Pharmacological inhibition of PKCβ inhibits MIF-induced IL-8 induction in BM-MSC
We We treated AML stimulated BM-MSC with LY294002 (a PI3K/Akt inhibitor), PD098059 (a MAPK kinase (MEK) 1 inhibitor) or Ro-31-8220 (a PKC pan inhibitor) to determine which pathway/s regulate AML induced BM-MSC IL-8 mRNA induction. We show that Ro-31-8220, the PKC inhibitor, was able to significantly inhibit IL-8 expression by approximately 80%, while LY294002 and PD098059 had little or no effect ( Figure 4A ). Similarly, we found that Ro-31-8220 was able to inhibit IL-8 expression by circa 90% in experiments where BM-MSC were directly activated using rhMIF (rather than AML cells) ( Figure 4B ). However in addition we observed that PD98059, was able to moderately inhibit rhMIF induced IL-8 mRNA induction in BM-MSC by approximately 30% ( Figure 4B ).
To clarify whether PKC, MAPK or both are activated in response to MIF, we performed
Western blot analysis on BM-MSC for specific phosphorylation of PKC isoforms, MAPK or AKT in response to MIF activation. BM-MSC were activated by AML for 15 minutes or MIF treatment (100ng/ml) for various times. We initially show that MIF and AML both induce phosphorylation of PKC α/βII and PKC β in BM-MSC ( Figure 4C ). BMSC from four patient samples treated with MIF had no increase in phosphorylation of AKT and MAPK ( Figure 4D ).
Next, the PKC isoform specific inhibitors Go6976 (PKCα/β) and enzastuarin (PKCβ), were used to block MIF induced IL-8 expression in BM-MSC. Both inhibitors showed inhibition of MIF induced IL-8 up-regulation ( Figure 4E ). Finally we used lentiviral viral mediated knockdown (KD) for PKCβ, confirming reduced mRNA expression of PKCβ after transduction of BM-MSC with control KD or PKCβ KD virus ( Figure 4F ). We then demonstrate that knockdown of PKCβ inhibits MIF induced IL-8 mRNA expression ( Figure   4G ). Together these results confirm that MIF induced IL-8 expression in AML patient derived BM-MSC requires PKCβ.
Targeting the MIF-PKCβ-IL-8 axis disrupts BM-MSC induced protection of primary human AML blasts
Finally to examine the effect of blocking IL-8 on BM-MSC protection and survival of primary AML blasts we co-cultured primary AML blasts derived from treatment-naïve AML patients with BM-MSC (either control KD or IL-8 KD). Firstly we used lentiviral viral mediated knockdown (KD) for IL-8. Figure 5A and 5B shows the mRNA expression and protein expression of IL-8 after transduction of BM-MSC with control KD or IL-8 KD virus. Figure 5C demonstrates that knockdown of IL-8 inhibits MIF induced IL-8 mRNA expression. Next we show that KD of IL-8 in BM-MSC significantly inhibits AML survival when in co-culture compared to control KD BM-MSC ( Figure 5D ). Finally, blocking the IL-8R using SB225002
inhibited AML survival when cultured with BM-MSC ( Figure 5E ). Taken together, these results identify a novel pro-tumoral regulatory pathway in the AML microenvironment.
Discussion
AML is primarily a disease of the elderly with a median age at diagnosis in the Swedish
Acute Leukemia Registry of 72 years (29) . Outcomes for the 75% of patients who get AML over the age of 60 remain generally poor, largely because the intensity and side effects of existing curative therapeutic strategies (which are commonly used to treat younger fitter patients) coupled with patient co-morbidities, frequently limit their use in this older less fit population (30) . Accordingly, there is an urgent need to identify pharmacologic strategies to tackle AML, which are not only effective but can also be tolerated by both older and less well patients. It is envisaged that treatments which target the tumor microenvironment may well help realize this goal.
Here we report a novel survival pathway within the human AML microenvironment which functions as a feedback/autocrine loop involving the constitutive expression of the chemokine MIF by the AML blasts which in turn induces IL-8 expression in BM-MSC.
Interestingly, another group showed that the repertoire of constitutive in vitro chemokine release from AML shows variation between different AML patient samples (31) . We find that although baseline expression of MIF by AML varies between patient samples tested, all samples analyzed expressed MIF. Moreover in co-culture experiments AML patient derived BM-MSC's were found to be ubiquitously responsive to AML derived MIF which resulted in an increase in IL-8 expression by the BM-MSCs. This is in keeping with similar reports on other cytokine pathways which have shown that BM-MSC can constitutively express various chemokines (32), and AML cells are able to respond to these chemokines (32, 33) . In this study we also examined the genotype of six BM-MSC used for the experiments and found three of six to be normal and the other three the genotyping failed (supplementary table 2 ). hours. AML blast number was assessed using a trypan blue exclusion hemocytometerbased counts. The Mann-Whitney U test was used to compare between treatment groups (* = p<0.05).
This is apparently in contrast to
